March 27, 2018 / 12:12 PM / 6 months ago

BRIEF-Altimmune Announces Positive Data From Its Phase 2A Study Of Nasovax Intranasal Influenza Vaccine

March 27 (Reuters) - Altimmune Inc:

* ALTIMMUNE ANNOUNCES POSITIVE DATA FROM ITS PHASE 2A STUDY OF NASOVAX INTRANASAL INFLUENZA VACCINE AND PROVIDES AN UPDATE ON ITS PHASE 1B STUDY OF HEPTCELL TARGETED IMMUNOTHERAPY IN CHRONIC HEPATITIS B INFECTION

* ALTIMMUNE INC - HEPTCELL VACCINE WAS WELL TOLERATED BUT T-CELL IMMUNOGENICITY RESULTS WERE INCONCLUSIVE

* ALTIMMUNE - RESULTS FROM NASOVAX INTRANASAL FLU VACCINE PHASE 2A STUDY IN 60 HEALTHY INDIVIDUALS SHOWED 100% SEROPROTECTION IN MID- & HIGH-DOSE GROUPS Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below